Geron to Participate in the B. Riley Securities Virtual Oncology Conference
12 Janeiro 2024 - 10:30AM
Business Wire
Geron Corporation (Nasdaq: GERN), a late-stage clinical
biopharmaceutical company, today announced that John A. Scarlett,
M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to
participate in a fireside chat at the B. Riley Securities Virtual
Oncology Conference on Thursday, January 18th, 2024, at 10:30am
ET.
A webcast of the presentation will be available through the
Investors and Media section of Geron’s website under Events
following the presentation. The webcast will be archived and
available for replay for a period of 30 days.
About Geron
Geron is a late-stage biopharmaceutical company pursuing
therapies with the potential to extend and enrich the lives of
patients living with hematologic malignancies. Our first-in-class
investigational telomerase inhibitor, imetelstat, harnesses Nobel
Prize-winning science in a treatment that may alter the underlying
drivers of disease. The New Drug Application (NDA) for imetelstat
in lower risk myelodysplastic syndromes (LR MDS), based on the
results from the Phase 3 IMerge clinical trial, is currently under
review by the United States Food and Drug Administration (FDA) with
a Prescription Drug User Fee Act (PDUFA) target action date of June
16, 2024. Additionally, Geron currently has an ongoing pivotal
Phase 3 clinical trial evaluating imetelstat in relapsed/refractory
myelofibrosis (MF). To learn more, visit www.geron.com or follow us
on LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240112477562/en/
Aron Feingold Vice President, Investor Relations and Corporate
Communications
Kristen Kelleher Senior Manager, Investor Relations
investor@geron.com media@geron.com
Geron (NASDAQ:GERN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Geron (NASDAQ:GERN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024